CRL CANADA RESEARCH LAB

CRL Laboratories

Certificate of Analysis

High-Performance Liquid Chromatography

HGH Fragment 176-191 - 5mg

Tested for: Lexar

lab@domain.com

COA #:	**COA-2026-OLOL9G**	Analysis Date:	**08/03/2026**
Lot Number:	**HGF0001**	Appearance:	**Good**
Accession #:	**ACC-2026-88823**	Sample Matrix:	**Lyophilized**
Labeled Content:	**5mg**	Volume:	**3mL**
		Date Received:	**07/31/2026**

HGH Fragment 176-191 5mg
HGF0001

Method: **Full QC Panel**

Identity
HGH Fragment 176-191

Peptide Purity
99.68%

Fentanyl Free

Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	**99.68%**	%	**PASS**
Net Peptide Content	Report Only	**5.65**	mg	N/A
Identity (HPLC-RTM)	HGH Fragment 176-191	**Confirmed**	-	**PASS**
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	**Not Detected**	-	**PASS**

HPLC Chromatogram



Representative chromatogram. Conformity V1

HPLC Conformity Testing Results (2 samples tested)

Sample	Purity	NPC	ID	Result
Dedicated V0	99.68%	5.65 mg	Confirmed	**PASS**
Conformity V1	99.63%	5.48 mg	Confirmed	**PASS**
Mean	**99.22%**	**5.15 mg**	—	—
Std Dev	**0.0800%**	**0.0700 mg**	—	—

Harmon Lee

Harmon Lee
Reviewed and approved by:

COA #: **COA-2026-OLOL9G**
Issued: 8/3/2026

Heavy Metals Analysis (ICP-MS)

Test	Specification	Result	Status
Arsenic (As)	NMT 1.5 ppm	*Not Detected*	**PASS**
Cadmium (Cd)	NMT 0.5 ppm	*Not Detected*	**PASS**
Lead (Pb)	NMT 1.0 ppm	*Not Detected*	**PASS**
Mercury (Hg)	NMT 1.5 ppm	*Not Detected*	**PASS**
Chromium (Cr)	NMT 10.0 ppm	*Not Detected*	**PASS**

Sterility Testing (PCR)

Test	Specification	Result	Status
Sterility (PCR)	No Growth	**No Growth**	**PASS**

Endotoxin Testing (USP <85>)

Test	Specification	Result	Status
Endotoxin (USP <85>)	Report Result	**NMT 0.05 EU/mL**	**Reported**

About this result: Endotoxin is reported as a quantitative value. Acceptable limits vary by product type and matrix, so no universal pass/fail threshold applies to RUO products.

Notes & Methodology

1. Date Tested: 08/03/2026. Methods: Purity, Identity & Quantitation (HPLC).
2. The sample was confirmed to be HGH Fragment 176-191 by HPLC. Identification by chromatographic retention time comparison with a reference standard.
3. Elemental impurities analyzed by ICP-MS per USP <233> methodology. Acceptance criteria are internal laboratory quality screening limits for research-use materials and do not represent evaluation against any specific pharmacopeial monograph or product specification.
4. Endotoxin tested per USP <85> kinetic turbidimetric method. Acceptance criteria per client specification.
5. Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.

Harmon Lee

Harmon Lee
Reviewed and approved by:

COA #: **COA-2026-OLOL9G**
Issued: 8/3/2026